Provided by Tiger Fintech (Singapore) Pte. Ltd.

Qudian Inc.

2.72
-0.0550-1.99%
Volume:321.54K
Turnover:872.62K
Market Cap:514.23M
PE:101.25
High:2.77
Open:2.74
Low:2.66
Close:2.77
Loading ...

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

PR Newswire
·
28 Oct 2024

IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

PR Newswire
·
25 Oct 2024

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

GlobeNewswire
·
25 Oct 2024

Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

PR Newswire
·
25 Oct 2024

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

GlobeNewswire
·
23 Oct 2024

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire
·
22 Oct 2024

Discover 3 US Penny Stocks With Market Caps Over $70M

Simply Wall St.
·
22 Oct 2024

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

GlobeNewswire
·
16 Oct 2024

Asian Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

MT Newswires Live
·
10 Oct 2024

Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading

MT Newswires Live
·
04 Oct 2024

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

GlobeNewswire
·
28 Sep 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

GlobeNewswire
·
26 Sep 2024

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Business Wire
·
26 Sep 2024

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

PR Newswire
·
23 Sep 2024

Incyte Announces Promising New Data on Oncology Candidate at ESMO

Zacks
·
17 Sep 2024

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

PR Newswire
·
14 Sep 2024